NDA 022511 · Horizon
Vimovo
Esomeprazole Magnesium, Naproxen · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Apr 30, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
522
102 Phase 3, 23 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 6, 2017 Supplement 19 · Efficacy LabelLetter
- Apr 30, 2010 Original approval · Type 4 - New Combination LabelSummary ReviewPediatric Medical Review
2 products under this application
- VIMOVO · ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE; NAPROXEN 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
- VIMOVO · ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE; NAPROXEN 375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Esomeprazole" as an intervention, any sponsor and status, largest first.
- Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityPivotal-lookingRecruiting
International Agency for Research on CancerAcademic, hospital or other
NCT02047994 · 30,000 participants (planned) · Start Mar 2013 · Primary completion Dec 2033
Drug: Triple therapy · For: Helicobacter Pylori Infections; Atrophic Gastritis; Gastric Cancer
Sites: Riga, Latvia
- Community-based Helicobacter Pylori EradicationStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT00155389 · 5,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2015
Drug: Helicobacter pylori eradication · For: Helicobacter Pylori Infection
Sites: Taipei, Taiwan · 2 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00444275 · 3,029 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: esomeprazole (Nexium®); Xolaam® · For: GERD
Sites: Rouen, France
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00357682 · 2,557 participants · Start Mar 10, 2005 · Primary completion May 31, 2017
Drug: Esomeprazole; Esomeprazole and 1 more · For: Esophageal Cancer; Precancerous Condition
- Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00441727 · 2,426 participants · Start Feb 2007 · Primary completion Aug 2008
Drug: Esomeprazole 40 mg; Esomeprazole 20 mg and 1 more · For: Gastric Ulcer; Duodenal Ulcer
Sites: Birmingham, Alabama; Tucson, Arizona; Anaheim, California · 189 sites in all
- Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for ResponsePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00392002 · 2,000 participants · Start Oct 2005
Drug: Esomeprazole · For: Gastroesophageal Reflux
Sites: Mississauga, Canada; Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vimovo (Naproxen/Esomeprazole Mag)
2024 spending
$268K
Beneficiaries
26
119 claims
Per beneficiary
$10,301
$35.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,389,928 |
| 2021 | $6,376,099 |
| 2022 | $4,775,335 |
| 2023 | $3,389,170 |
| 2024 | $267,832 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, et al. · Int J Clin Pharmacol Ther 2015 · Comparative Study, Meta-Analysis
- Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials.
Floria DE, Obeidat M, Váncsa S, et al. · Gut Microbes 2025 · Systematic Review, Meta-Analysis
- Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E, Kim S, Kim B, et al. · Br J Clin Pharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ, Son BK, Kim GH, et al. · Aliment Pharmacol Ther 2019 · Clinical Trial, Phase III, Comparative Study
- Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.
Lee KN, Lee OY, Chun HJ, et al. · World J Gastroenterol 2022 · Randomized Controlled Trial
- Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study.
Xiao X, Zhang X, Wang J, et al. · Gut 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.